FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY

• US 20100040593A1
• Filed: 08/15/2008
• Published: 02/18/2010
• Est. Priority Date: 08/15/2008
• Status: Abandoned Application

• Current Assignee: Orthopeutics, L.P (Spinal Simplicity, LLC)
• Original Assignee: Orthopeutics, L.P (Spinal Simplicity, LLC)
• Inventors: Hedman, Thomas P., Slusarewicz, Paul
• Application Number:
  US12/192,746
• Publication Number:
  US 20100040593A1
• Time in Patent Office: Days
• US Class Current: 424/94.400
• CPC Class Codes: A61K 31/121 acyclic
• CPC Class Codes: A61K 31/13 Amines A61K31/04 takes precedence
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/7004 Monosaccharides having only carbon, hydrogen and oxygen atoms
• CPC Class Codes: A61K 38/45 Transferases (2)
• CPC Class Codes: A61K 9/0085 Brain, e.g. brain implants; Spinal cord
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders

Abstract

Improved methods and compositions for the treatment of native tissues with crosslinkers are provided. The methods and compositions will find particular use in increasing resistance to tearing, fissuring, rupturing, and/or delamination.

Claims

1. A method of inducing methylglyoxal (MG)-mediated cross-linking in a native tissue having naturally-occurring collagen crosslinks within a living human body comprising contacting said tissue with MG at 5-50 mM and any combination of the following in a composition of about pH 8.0-9.5:

(a) 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) buffer at 50-250 mM;

(b) 50-500 mM phosphate ions;

(c) sodium borohydride at about 1-5 mM; and

/or

(d) a surfactant.

2. The method of claim 1, wherein said MG is contacted in at a concentration of 20 mM in 100 mM 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) buffer at pH 9 with 100 mM phosphate ions.

3. The method of claim 1, wherein said tissue is located in a joint.

4. The method of claim 1, wherein said tissue is a spinal disc.

5-8. -8. (canceled)

9. A method of inducing proanthrocyanidin (PA)-mediated cross-linking in a native tissue having naturally-occurring collagen crosslinks within a living human body comprising contacting said tissue with about 0.025-0.5% w/v PA and any combination of the following in a composition of about pH 5-9.5:

(a) 50-25 mM Tris buffer; and

/or

(b) a surfactant.

10. The method of claim 9, wherein said PA is contacted at about 0.1% w/v of said composition containing 100 mM Tris buffer at pH 9.

11. The method of claim 9, wherein said tissue is located in a joint.

12. The method of claim 9, wherein said tissue is a spinal disc.

13. A method of inducing transglutaminase (TG)-mediated cross-linking in a native tissue having naturally-occurring collagen crosslinks within a living human body comprising contacting said tissue with a composition comprising about 0.5-5 U/ml TG and any combination of the following at about pH 7-8:

(a) 50-250 mM tris buffer; and

/or

(b) a surfactant.

14. The method of claim 13, wherein said TG is contacted at 2 U/ml in 100 mM Tris buffer at pH 8.

15. The method of claim 13, wherein said tissue is located in a joint.

16. The method of claim 13, wherein said tissue is a spinal disc.

17. A method of inducing 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC)-mediated cross-linking in a native tissue having naturally-occurring collagen cross-links within a living human body comprising contacting said tissue with about 2-10 mM EDC and any combination of the following in a composition of about pH 6.0:

(a) 50-150 mM; and

/or

(b) a surfactant.

18. The method of claim 17, wherein said EDC is contacted at a concentration of 5 mM in a buffer lacking amine or carboxyl groups.

19. The method of claim 18, wherein said buffer is 100 mM 2-(N-morpholino)ethanesulfonic acid (MES).

20. The method of claim 17, wherein said tissue is located in a joint.

21. The method of claim 17, wherein said tissue is a spinal disc.

22-25. -25. (canceled)

26. A method of inducing cross-linking in a native tissue having naturally-occurring collagen crosslinks within a living human body comprising contacting said tissue with a cross-linking agent and an anionic surfactant.

27. The method of claim 26, wherein the cross-linking agent is genipin, methylglyoxal, proanthrocyanidin, L-threose, D-threose, ribose, glyoxal, lysyl oxidase, an epoxy, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide or transglutaminase.

28. The method of claim 26, wherein said anionic surfactant is an alkyl sulfonate, sodium cholate, sodium deoxycholate, an alkyl benzene sulfonate, N-lauroylsarcosine, or a fatty acid salt.

29. The method of claim 26, wherein said tissue is located in a joint.

30. The method of claim 26, wherein said tissue is a spinal disc.

31. A composition of matter comprising about 5-50 mM methylglyoxal (MG) and about 50-250 mM EPPS at about pH 8.0-9.5 and 50-500 mM phosphate ions.

32. (canceled)

33. A composition of matter comprising about 0.025-0.5% w/v of proanthrocyanidin (PA) and about 50-250 mM Tris at about pH 8.0-9.5.

34. A composition of matter comprising about 20-100 mM L- or D-threose (LT or DT) and about 50-250 mM EPPS at about pH 8.0-9.5 and phosphate ions at about 50-500 mM.

35. A method of inducing cross-linking in a native tissue having naturally-occurring collagen crosslinks within a living human body comprising contacting said tissue with any combination of methylglyoxal at 5-50 mM, genipin at about 20 mM or less, about 0.025-0.5% w/v proanthrocyanidin, about 0.5-5 U/ml transglutaminase, 2-10 mM 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC), 20-100 mM L- or D-threose.

36. The method of claim 35, wherein said combination comprises genipin at about 20 mM or less.

37. The method of claim 36, wherein said tissue is contacted with methylglyoxal at 5-50 mM and genipin at about 20 mM or less.

38. The method of claim 36, wherein said tissue is contacted with 20-100 mM L- or D-threose and genipin at about 20 mM or less.

39. The method of claim 36, wherein said tissue is contacted with about 0.025-0.5% w/v proanthrocyanidin and genipin at about 20 mM or less.

40. The method of claim 36, wherein said tissue is contacted with about 0.025-0.5% w/v about 0.5-5 U/ml transglutaminase and genipin at about 20 mM or less.